Idiopathic pulmonary fibrosis (IPF) is a progressive disorder that results in the scarring of the lungs for an unknown reason. PRM-151, a recombinant human pentraxin 2 protein, has shown significant activity against IPF in previous studies. This study aims to evaluate the 76-week results of an open-label extension study that assessed the use of PRM-151 for IPF.
This analysis of an open-label extension study included a total of 1111 patients with IPF who had received concomitant IPF therapy. All the patients were assigned to receive PRM-151 in 28-week cycles on days 1, 3, 5, and 7. The primary objective of the study was the long-term safety and tolerability of PRM-151.
Adverse events remained consistent with long-term IPF sequelae. Twenty-eight percent of patients had serious adverse events, including pneumonia (5%), IPF exacerbation (4%), IPF progression (4%), and chest pain (2%). In addition, 19% of the patients had severe adverse events, mainly IPF exacerbation and IPF progression. Two patients (2%) suffered from life-threatening adverse events. However, persistent treatment was observed in patients who continued the treatment.
The research concluded that in patients with IPF, long-term treatment with PRM-151 was well-tolerated with persistent effects on the percentage of predicted FVC and 6-min walking distance.